Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0684249 (lung carcinoma)
 23,830 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Two patients with carcinoma of the lung were studied with 99mTc-stannous pyrophosphate. Resolution of scintigraphic activity was observed postoperatively in one patient, while the second patient showed an asymmetric pattern of radionuclide uptake and radiographic changes as well as clinical findings of hypertrophic pulmonary osteoarthropathy.
 ...
PMID:Manifestations of hypertrophic pulmonary osteoarthropathy in patients with carcinoma of the lung. Demonstration by 99mTc-pyrophosphate bone scans. 93 85

In two patients with carcinoma of the lung, abnormal findings on skeletal imaging using 99mTc-diphosphonate correctly suggested the diagnosis of hypertrophic pulmonary osteoarthropathy, which was later confirmed radiographically. A scintigraphic pattern of abnormal tracer localization distinguishes this benign condition of bone from bony metastases.
 ...
PMID:Detection of hypertrophic pulmonary osteoarthropathy of skeletal imaging with 99mTc-labeled diphosphonate. 111 Oct 6

Squamous, large cell, and adenocarcinoma, collectively termed non-small cell lung cancer (NSCLC), are diagnosed in approximately 75% of patients with lung cancer in the United States. The treatment of these three tumor cell types is approached in virtually identical fashion because, in contrast to small cell carcinoma of the lung, NSCLC more frequently presents with localized disease at the time of diagnosis and is thus more often amenable to surgical resection but less frequently responds to chemotherapy and irradiation. Cigarette smoking is etiologically related to the development of NSCLC in the great majority of cases. Genetic mutations in dominant oncogenes such as K-ras, loss of genetic material on chromosomes 3p, 11p, and 17p, and deletions or mutations in tumor suppressor genes such as rb and p53 have been documented in NSCLC tumors and tumor cell lines. NSCLC is diagnosed because of symptoms related to the primary tumor or regional or distant metastases, as an incidental finding on chest radiograph, or rarely because of a paraneoplastic syndrome such as hypercalcemia or hypertrophic pulmonary osteoarthropathy. Screening smokers with periodic chest radiographs and sputum cytologic examination has not been shown to reduce mortality. The diagnosis of NSCLC is usually established by fiberoptic bronchoscopy or percutaneous fine-needle aspiration, by biopsy of a regional or distant metastatic site, or at the time of thoracotomy. Pathologically, NSCLC arises in a setting of bronchial mucosal metaplasia and dysplasia that progressively increase over time. Squamous carcinoma more often presents as a central endobronchial lesion, while large cell and adenocarcinoma have a tendency to arise in the lung periphery and invade the pleura. Once the diagnosis is made, the extent of tumor dissemination is determined. Since most NSCLC patients who survive 5 years or longer have undergone surgical resection of their cancers, the focus of the staging process is to determine whether the patient is a candidate for thoracotomy with curative intent. The dominant prognostic factors in NSCLC are extent of tumor dissemination, ambulatory or performance status, and degree of weight loss. Stages I and II NSCLC, which are confined within the pleural reflection, are managed by surgical resection whenever possible, with approximate 5-year survival of 45% and 25%, respectively. Patients with stage IIIa cancers, in which the primary tumor has extended through the pleura or metastasized to ipsilateral or subcarinal lymph nodes, can occasionally be surgically resected but are often managed with definitive thoracic irradiation and have 5-year survival of approximately 15%.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:Non-small cell lung cancer. Part I: Biology, diagnosis, and staging. 164 34

Squamous, large cell, and adenocarcinoma, collectively termed non-small cell lung cancer (NSCLC), are diagnosed in approximately 75% of patients with lung cancer in the United States. The treatment of these three tumor cell types is approached in virtually identical fashion because, in contrast to small cell carcinoma of the lung, NSCLC more frequently presents with localized disease at the time of diagnosis and is thus more often amenable to surgical resection but less frequently responds to chemotherapy and irradiation. Cigarette smoking is etiologically related to the development of NSCLC in the great majority of cases. Genetic mutations in dominant oncogenes such as K-ras, loss of genetic material on chromosomes 3p, 11p, and 17p, and deletions or mutations in tumor suppressor genes such as rb and p53 have been documented in NSCLC tumors and tumor cell lines. NSCLC is diagnosed because of symptoms related to the primary tumor or regional or distant metastases, as an incidental finding on chest radiograph, or rarely because of a paraneoplastic syndrome such as hypercalcemia or hypertrophic pulmonary osteoarthropathy. Screening smokers with periodic chest radiographs and sputum cytologic examination has not been shown to reduce mortality. The diagnosis of NSCLC is usually established by fiberoptic bronchoscopy or percutaneous fine-needle aspiration, by biopsy of a regional or distant metastatic site, or at the time of thoracotomy. Pathologically, NSCLC arises in a setting of bronchial mucosal metaplasia and dysplasia that progressively increase over time. Squamous carcinoma more often presents as a central endobronchial lesion, while large cell and adenocarcinoma have a tendency to arise in the lung periphery and invade the pleura. Once the diagnosis is made, the extent of tumor dissemination is determined. Since most NSCLC patients who survive 5 years or longer have undergone surgical resection of their cancers, the focus of the staging process is to determine whether the patient is a candidate for thoracotomy with curative intent. The dominant prognostic factors in NSCLC are extent of tumor dissemination, ambulatory or performance status, and degree of weight loss. Stages I and II NSCLC, which are confined within the pleural reflection, are managed by surgical resection whenever possible, with approximate 5-year survival of 45% and 25%, respectively. Patients with stage IIIa cancers, in which the primary tumor has extended through the pleura or metastasized to ipsilateral or subcarinal lymph nodes, can occasionally be surgically resected but are often managed with definitive thoracic irradiation and have 5-year survival of approximately 15%.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:Non-small cell lung cancer. Part II: Treatment. 171 39

A case of hypertrophic pulmonary osteoarthropathy (HPO) associated with carcinoma of the lung is reported. HPO in this patient was documented by Tc-99m methylene diphosphonate scans over a period of seven months. He was treated solely by antitumor chemotherapy, and his HPO was inactivated in three months. Whereas most reports refer to surgery, vagotomy, or radiotherapy for the treatment of lung carcinoma, this case demonstrates the effect of palliative chemotherapy in inactivating HPO in a rather short period of time.
 ...
PMID:Hypertrophic pulmonary osteoarthropathy inactivated by antitumor chemotherapy. 407 Jun 70

The case of a patient with small-cell carcinoma of the lung, bone marrow metastases, and hypertrophic pulmonary osteoarthropathy is reported. Normal growth hormone serum concentrations contrasted with significant increases in ACTH, beta-MSH, calcitonin, and gastrin. A hormonal etiology has previously been suggested for hypertrophic pulmonary osteoarthropathy. Our findings indicate that the hormone responsible for hypertrophic pulmonary osteoarthropathy may be an APUD polypeptidic substance, that differs from immunoreactive GH but is related to somatomammotropins.
 ...
PMID:[Hypertrophic pulmonary osteoarthropathy with paraneoplastic secretion of four hormones. Considerations on pathogenesis (author's transl)]. 627 40

A patient with hypertrophic osteoarthropathy (HO) secondary to large cell anaplastic carcinoma of the lung was treated with combination chemotherapy (CAP-1). Systemic tumor symptoms resolved within 3 wk. Relief from the bone and articular symptoms of HO was noted after 3 months of treatment, coincident with a partial remission (greater than 50% tumor regression). Objective improvement in the radionuclide bone scan and radiographic periostitis was demonstrated after 6 months. Symptomatic improvement continued despite evidence of tumor progression after 10 months of treatment. Systemic chemotherapy should be considered in the management of symptomatic osteoarthropathy secondary to unresectable bronchogenic carcinoma.
 ...
PMID:Reversal of hypertrophic osteoarthropathy after chemotherapy for bronchogenic carcinoma. 735 75

In a 49-year-old man, large-cell carcinoma of the lung was accompanied by raised serum levels of growth hormone (GH) and growth hormone-releasing hormone (GHRH) and hypertrophic osteoarthropathy. Immunohistochemically the tumour contained GHRH but not GH. The osteoarthropathy disappeared after resection of the primary tumour and did not reappear after its recurrence. The high serum GH level presumably was due to ectopic GHRH production in the tumour. The hypertrophic osteoarthropathy was not clearly attributable to these hormones.
 ...
PMID:Lung cancer containing growth hormone-releasing hormone associated with hypertrophic osteoarthropathy. Case report. 779 60

A 73-year-old man had complained of painful swelling in the upper and lower extremities for several months before detection of small cell lung carcinoma. A bone scan showed abnormal symmetrical accumulations in the extremities, but periosteal proliferation was not demonstrated by X-ray. When a complete remission was obtained by chemoradiotherapy, the joint manifestation also subsided completely. In almost all reported cases, hypertrophic pulmonary osteoarthropathy was observed in all patients with non-small cell lung carcinoma. To our knowledge, this is the first case report of hypertrophic pulmonary osteoarthropathy associated with small cell lung carcinoma published in the English literature.
 ...
PMID:A case of small cell carcinoma of the lung associated with hypertrophic pulmonary osteoarthropathy. 869 7

A 73-year-old male with stage IV lung adenocarcinoma presented with leg swelling and clubbing of the fingers on both hands upon physical examination, and bone scintigrams demonstrated marked accumulation of 99mTc-MDP in the long bones adjacent to the patellae. A diagnosis of hypertrophic pulmonary osteoarthropathy associated with primary lung cancer was made. Radiofrequency ablation (RFA) was utilized for cytoreduction, because the patient refused chemotherapy. One-month follow-up CT scans revealed low density of the ablated area associated with ablation necrosis. Cytoreduction by RFA rapidly alleviated the arthralgia and swelling, but not the clubbing of fingers. Follow-up bone scintigrams demonstrated a reduction in patellar uptake after RFA.
Lung Cancer 2002 Dec
PMID:Tumor debulking by radiofrequency ablation in hypertrophic pulmonary osteoarthropathy associated with pulmonary carcinoma. 1244 55


1 2 Next >>